Construction of a Novel Virus That Targets HIV-1-Infected Cells and Controls HIV-1 Infection  by Schnell, Matthias J et al.
Cell, Vol. 90, 849±857, September 5, 1997, Copyright 1997 by Cell Press
Construction of a Novel Virus That Targets
HIV-1-Infected Cells and Controls HIV-1 Infection
Matthias J. Schnell,* J. Erik Johnson,² 1996b). VSV causes an extremely rapid cytopathic infec-
tion in most animal cells including human T cells inLinda Buonocore,* and John K. Rose*³
*Departments of Pathology and Cell Biology culture but is normally nonpathogenic in humans (for
review, see Wagner and Rose, 1996). Within 2 to 3 hr²Department of Genetics
Yale University School of Medicine after infection, VSV blocks host cell protein synthesis
and within 8 hrproduces very large quantities of progenyNew Haven, Connecticut 06510
virus particles that bud from the cell surface prior to cell
lysis. VSV has a nonsegmented, negative strand RNA
genome that is copied in the cytoplasm of infected cellsSummary
by the viral RNA polymerase to generate five mRNAs
encoding the five structural proteins. Only one of theseWe describe a recombinant vesicular stomatitis virus
proteins, a glycoprotein designated G, is present in thelacking its glycoprotein gene and expressing instead
viral membrane and is responsible for the very broadthe HIV-1 receptor CD4 and a coreceptor, CXCR4. This
host range of VSV. G protein recognizes cell surfacesvirus was unable to infect normal cells but did infect,
and catalyzes fusion of the viral membrane with cellularpropagate on, and kill cells that were first infected
membranes (Florkiewicz and Rose, 1984; Riedel et al.,with HIV-1 and therefore had the HIV membrane fusion
1984). Foreign membrane proteins such as CD4 andprotein on their surface. Killing of HIV-1-infected cells
other viral membrane proteins can be expressed at verycontrolled HIV infection in a T cell line and reduced
high levels from the genome of recombinant VSVs, andtiters of infectious HIV-1 in the culture by as much as
these molecules are then incorporated at high levels104-fold. Such a targeted virus could have therapeutic
into the viral membrane along with G protein (Schnellvalue in reducing HIV viral load. Our results also dem-
et al., 1996b).onstrate a general strategy of targeting one virus to the
In the studies reported here, we have generated VSVenvelope protein of another virus to control infection.
recombinants with a complete deletion of the VSV G
gene and have substituted instead the genes for CD4
Introduction and CXCR4. These viruses assemble particles con-
taining both CD4 and CXCR4 in their envelopes and are
To cause infection, membrane-enveloped viruses such targeted specifically to infect HIV-1-infected cells.
as human immunodeficiency virus type 1 (HIV-1) must
first bind receptors at the cell surface and subsequently
Resultsfuse their own membrane with that of the cell. This fusion
process releases the viral genetic material into the cyto-
Recovery of VSV Recombinants Expressingplasm and initiates infection. Entry of HIV-1 into cells
CD4 and CXCR4has long been known to require virus binding to the cell
Genetic engineering of nonsegmented negative strandsurface molecule CD4 (Maddon et al., 1986; Sattentau
RNA viruses such as VSV is complicated by the fact thatand Weiss, 1988), and recent studies have defined
the minimal infectious unit of the virus is not RNA butchemokine receptor molecules CXCR4 (Berson et al.,
rather the viral RNA genome in a ribonucleoprotein com-1996; Feng et al., 1996), CCR5 (Alkhatib et al., 1996;
plex composed of nucleocapsid (N) and polymeraseChoe et al., 1996; Deng et al., 1996; Doranz et al., 1996;
proteins (L and P). Infectious VSV can be recoveredDragic et al., 1996), and CCR3 (Choe et al., 1996; Doranz
from plasmid DNA as follows. Four separate plasmidset al., 1996) as coreceptors required for entry. HIV entry
expressing the full-length antigenomic VSV RNA and theoccurs in stages: initial binding of the viral envelope
N, P, and L genes under control of bacteriophage T7protein (designated gp120/41) to CD4 is followed by
promoters are transfected into cells already infectedconformational changes that allow binding to corecep-
with a vaccinia virus recombinant expressing T7 RNAtor and subsequent coalescence of the viral and cellular
polymerase (vTF7-3). Intracellular assembly of the anti-membranes (Lapham et al., 1996; Trkola et al., 1996; Wu
genomic RNA into nucleocapsids is followed by VSVet al., 1996). HIV-infected cells express gp120/41 on the
replication and transcription to generate infectious, rep-cell surface during infection and prior to its incorporation
lication-competent VSV (Fuerst et al., 1986; Lawson etinto budding HIV-1 particles. The presence of such mol-
al., 1995; Whelan et al., 1995). Additional genes can beecules suggests the possibility that another virus might
expressed from extra transcription units introduced intobe engineered to carry HIV-1 receptor and coreceptor in
the VSV genome (Schnell et al., 1996a).its envelope and target specifically these HIV-1-infected
We reported previously the construction of a VSV re-cells.
combinant expressing the CD4 protein in addition to theRecent studies from our laboratory have focused on
five VSV proteins N, P, M, G, and L (Schnell et al., 1996b).developing vesicular stomatitis virus (VSV) as a high
To generate a VSV recombinant expressing CD4 andlevel expression vector capable of incorporating foreign
CXCR4 instead of VSV G, the upstream VSV G geneproteins into the viral envelope (Schnell et al., 1996a,
was deleted from the VSV-CD4 construct (Figure 1). The
recovery of virus, designated VSVDG-CD4, was then
accomplished by including a complementing plasmid³To whom correspondence should be addressed.
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Figure 1. Diagrams of Recombinant VSV Ge-
nomes
The order of the genes in wild-type VSV and
in the recombinant VSVs described is shown.
Each extra gene was inserted so that it con-
tained the appropriate signals specifying VSV
polymerase transcription initiation and termi-
nation. The details of plasmid constructions
and derivation of the recombinant viruses are
given in Experimental Procedures. The genes
are transcribed from left to right from the neg-
ative strand RNA genome that is shown in the
39-59 orientation.
encoding VSV G protein in addition to those encoding the virus particles were purified from the medium. Viral
proteins were then separated by SDS-PAGE and de-N, P, and L. We next added the gene encoding CXCR4
at the position downstream of CD4 and recovered the tected by staining with Coomassie blue (Figure 3A). The
wild-type virus contains the L, G, N, and M proteins (Pvirus, designated VSVDG-CC4. Because the recovered
viruses are capable of only a single round of infection is a minor protein comigrating with N), while the VSVDG-
CD4 and VSVDG-CC4 viruses lack G but contain a newon BHK cells, they were initially recovered and grown
on cells infected with a vaccinia virus encoding the T7 protein of z55,000 Da, the size expected for CD4. In a
previous study, we determined that the amount of CD4RNA polymerase and transiently expressing a comple-
menting VSV G protein from a transfected plasmid DNA. present in radiolabeled VSV-CD4 virions was about 25%
of the levelof VSV G (Schnell et al., 1996b). We compared
the amount of Coomassie-stained CD4 in those virionsA Cell Line Expressing VSV G Protein Allows
Growth of the Defective Viruses versus the VSVDG-CD4 and VSVDG-CC4 virions shown
here and determined that CD4 was incorporated withIn order to grow the VSVDG-CD4 and VSVDG-CC4 virus
in the absence of vaccinia virus, we next generated a the same high efficiency relative to the other VSV pro-
teins (data not shown).BHK cell line expressing the VSV G protein from an
inducible promoter (Shockett et al., 1995). Figure 2 The presence of CD4 in the particles was also verified
by Western blotting (Figure 3B, lanes 2 and 3) Theshows that the VSVDG-CC4 virus forms plaques on this
cell line, indicating multiple rounds of infection. Titers CXCR4 protein was not detected in VSVDG-CC4 by
staining but was readily detected by Western blottingobtained after growing the defective viruses on this cell
line were in the range of 0.5 3 106 to 1 3 106 pfu/ml. (Figure 3B, lane 6). The lack of detection of CXCR4 in
virions by Coomassie blue staining may be because itThese titers are reduced at least 1000-fold compared
to those of wild-type VSV, presumably because the lev- is present at lower levels than CD4, because it is broad
band obscured by VSV N protein, or because proteinsels of G protein provided by the complementing cell
line are low compared to those expressed in wild-type that are extremely hydrophobic do not bind the stain.
Budding of VSV in the absence of VSV G protein isinfection.
known to be approximately 20-fold less efficient than
budding in its presence (Knipe et al., 1977). Similar re-Incorporation of CD4 and CXCR4 into the
Recombinant Viruses sults have been obtained for rabies virus (Mebatsion et
al., 1996). Although the amounts of protein detected byTo determine if the CD4 and CXCR4 molecules were
expressed from the defective viruses and incorporated staining in Figure 3A appear similar for all viruses, it
should be noted that the virus loaded in lanes 2 and 3into virus particles, we infected BHK cells (not express-
ing VSV G) with VSVDG-CD4 or VSVDG-CC4 that had was derived from 107 infected BHK cells, while the wild-
type virus in lane 1 was from only 2 3 105, or 50-foldbeen grown on the BHK-G line (multiplicity of infection
[moi] 5 5). After 16 hr, when all cells had been killed, fewer infected cells. Our results not only confirm the
Figure 2. VSVs Lacking the G Gene Form
Plaques on a Complementing Cell Line
BHK-G cells were seeded on 6-well plates
(1.5 3 105 cells each well), and G protein ex-
pression was induced by removal of tetracy-
cline. The indicated dilutions of 100 ml of the
VSVDG-CD4 virus (1022, 1023, and 1024) were
added 16 hr later followed by addition of 2
ml of DME containing 2% methylcellulose.
Cells were incubated for 48 hr and then
stained with napthalene black to visualize the
small plaques. Wild-type VSV plaques are
much larger and are visible after 18 hr, but
plaque formation by the defective virus on
this cell line was slower, probably because
of the reduced level of complementing VSV
G protein expressed.
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Infection of HIV-1 Infected Cells by VSVDG-CC4
Because cells infected with HIV-1 have the gp120/41
envelope protein on their surface, we reasoned that it
might be possible to infect these cells with VSVDG-CC4.
The gp120/41 molecules present on the cell surface
should bind to CD4 and CXCR4 on the virus surface
and promote fusion of the viral and cell membranes. To
test this possibility, we infected a human T cell line
(Jurkat) with HIV-1 IIIB. At 5 days postinfection, when
control experiments showed that about half of the cells
were infected with HIV-1, we added VSVDG-CC4 virus.
Two control cultures, one infected with HIV-1 only and
another infected with VSVDG-CC4 only, were followed
in parallel. We initially followed infection by HIV-1 and
VSVDG-CC4 using indirect immunofluorescence mi-
croscopy to detect both HIV-1 proteins and VSV nucleo-
capsid (N) protein. An example of results from the immu-
nofluorescence analysis at 19 days after HIV infection
is shown in Figure 5 along with a Nomarski image of the
Figure 3. CD4 and CXCR4 Are Incorporated into Virus Particles same field of cells. A compilation of the immunofluores-
Purified particles of wild-type VSV, VSVDG-CD4, or VSVDG-CC4 cence data obtained throughout the experiment is
were separated by SDS-PAGE and their proteins visualized by Coo- graphed in Figure 6. The fields shown in Figure 5 illus-
massie blue staining (A) or Western blotting with sheep anti-CD4 trate that in the control culture infected with HIV-1 only,
antibody or monoclonal antibody 12CA5 to the HA epitope tag in nearly all cells stained positive for HIV antigens (A and
CXCR4 (B). The CXCR4 protein was not detected in VSVDG-CC4
B) while none of the cells stained positive for VSV Nby staining, perhaps because it contains seven membrane-spanning
protein (Figure 5C). In the cells infected with HIV-1 andsegments and does not bind the stain, but it was readily detected
VSVDG-CC4, only a small fraction of the cells were posi-by Western blotting (B, lane 6).
tive for HIV-1 antigens (Figures 5D and 5E) and the ma-
jority of those cells were also positive for VSV N protein
(Figure 5F), indicating that they had been superinfectedimportance of VSV G protein in driving highly efficient
with VSVDG-CC4. We also noted rare cells that werevirus budding but also illustrate that significant amounts
strongly positive for VSV N protein expression but had
of virus production occur even in the absence of VSV
only little or no HIV protein evident. These cells may
G protein.
result from shut off of cellular and HIV protein synthe-
To examine the morphology of the recombinant virus
sis by VSVDG-CC4 or from other mechanisms of in-
particles and to verify that CD4 was exposed on the fection (see Discussion). In Jurkat cells infected with
viral membrane, we examined purified virus particles by VSVDG-CC4 only, noneof thecells showed the presence
electron microscopy after labeling with antibody to CD4 of HIV or VSV N antigens (Figures 5H±5J).
and a gold-conjugated secondary antibody. Photo- From the quantitation in Figure 6, it is evident that
graphs of negatively stained virus particles are shown when cells were infected with HIV-1 alone, the percent-
in Figure 4. Wild-type VSV particles contained visible G age of HIV-11 cells rose to nearly 100% and remained
protein spikes (arrows) and did not bind antibody to high throughout the experiment. When cells were first
CD4, while the VSVDG-CD4 or VSVDG-CC4 viruses infected with HIV-1 and subsequently infected with
lacked visible spikes and did bind anti-CD4 antibodies. VSVDG-CC4, the percentage of HIV1 cells began to de-
The antibody to the HA tag on CXCR4 that was used in crease at day 14 and plateaued at day 21 to levels
Western blotting (Figure 3B) to show the presence of between 5% and 10% HIV1. In addition, Figure 6 shows
CXCR4 in the virions was not suitable for electron mi- that the percentage of HIV-11 cells that were also in-
croscopy because the HA tag is expected to be inside fected with VSVDG-CC4 increased and then reached a
plateau at around 90% to 95%. It therefore appears thatthe membrane.
Figure 4. Visualization of CD4 in the Enve-
lopes of VSVDG-CD4 and VSVDG-CC4 with
Immunoelectron Microscopy
Purified wild-type VSV, VSVDG-CD4, or
VSVDG-CC4 particles were negatively stained
with phosphotungstic acid after labeling with
a monoclonal antibody directed to CD4 fol-
lowed by gold-conjugated goat anti-mouse
IgG particles. Wild-type VSV particles con-
tained visible spikes of VSV G protein trimers
(arrows) and did not bind antibody to CD4
(wild-type VSV, left panel), while VSVDG-CD4
or VSVDG-CC4 bound anti-CD4 antibody and
did not show visible spikes on the surface.
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Figure 5. Analysis of HIV-1 and VSVDG-CC4
Infection by Immunofluorescence Micro-
scopy
Duplicate cultures of Jurkat cells were in-
fected with HIV-1 IIIB and 5 days later super-
infected with VSVDG-CC4 (D±F) or propa-
gated without superinfection (A±C). Jurkat
cells that were uninfected with HIV-1 were
also infected with VSVDG-CC4 (G±I). Four-
teen days after the VSVDG-CC4 infection,
cells were fixed and labeled with a mouse
monoclonal antibody to VSV N protein and a
secondary, affinity-purified, rhodamine-con-
jugated anti-mouse antibody (detected in [C],
[F], and [I]) and with a human polyclonal anti-
HIV immune globulin followed by affinity-puri-
fied, FITC-conjugated anti-human antibodies
(detected in [B], [E], and [H]). (A), (D), and (G)
show Nomarski images of the same fields of
cells shown stained in the two images to their
right.
cells infected with HIV-1 are rapidly superinfected with particles, we repeated the experiment shown in Figures
5 and 6 but instead followed HIV-1 titers and release ofVSVDG-CC4 and killed before high levels of HIV-1 can
be released. A balance is then reached between the two reverse transcriptase (RT) into the medium (Figures 7A
and 7B). At the time of addition of VSVDG-CC4 at 3viruses where HIV infection is controlled by VSVDG-
CC4 infection and maintained at low levels. Very similar days after HIV-1 infection, HIV titers and RT levels in the
medium were low. In thecontrol cells infected with HIV-1results were obtained in an experiment performed with
the H9 T cell line, another cell line in which HIV-1 IIIB alone or in the cells superinfected with VSVDG-CC4,
both the HIV titers and RT activity peaked at 10 daysgrows well.
We also tested the possibility that the VSVDG-CD4 after infection. There was then a decline in RT activity
by day 14 in cells superinfected with VSVDG-CC4 andvirus lacking the coreceptor gene might infect HIV-1-
infected cells. In one experiment, we observed a low a leveling off at about 10% of the RT level seen in control
cells. The results with titers of infectious HIV-1 werelevel of infection by VSVDG-CD4 (about 10% of that
observed with VSVDG-CC4). However, the initial infec- much more dramatic, with a complete disappearance
of infectious HIV-1 (.4 logs below the control) at daytion could be completely neutralized with antibody to
VSV G, indicating that a trace of G protein sufficient to 14 followed by a fluctuation at levels of only 0 to 39
infectious particles per milliliter out to day 34. Thesestart infection must have been present in the virions.
This G protein was presumably carried into the BHK cell titers should be compared to persistent titers of z104/
ml for the control culture that was not infected withline from the input virus grown in the BHK-G line and
then incorporated into exiting virions. Interestingly, once VSVDG-CC4.
The RT results were consistent with what we had seenthe infection was established in HIV-infected Jurkat
cells, it persisted for several weeks, indicating that the previously with the immunofluorescence in Figure 6, but
the much larger decreases in infectious HIV titers werevirus could propagate without encoding its own core-
ceptor. Presumably budding virions can pick up cell- not expected. These lower titers could be explained if
the VSVDG-CC4 infection selected for HIV-infected cellsencoded coreceptor and are then able to propagate.
However, control of HIV-1 infection was not as strong that expressed little or no HIV envelope and thus pro-
duced HIV particles lacking envelope but containing RT.as with VSVDG-CC4, indicating that it is preferable to
have the virus encode high levels of the coreceptor.
Because the control of HIV infection was less effective
Anti-CD4 or Anti-gp120 Block Infectionwithout coreceptor, we did not pursue further studies
by VSVDG-CC4with this virus.
We also performed control neutralization experiments
(Table 1) to verify that entry of VSVDG-CC4 into HIV-VSVDG-CC4 Infection Controls Release
infected cells was dependent on CD4 and gp120.in Infectious HIV-1
VSVDG-CC4 was incubated with antibody to CD4, neu-To obtain measurements of the effects of VSVDG-CC4
on production of infectious HIV-1 and onrelease of HIV-1 tralizing antibody to VSV-G, or without antibody before
Control of HIV-1 Infection by a Targeted Virus
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Figure 6. Quantitation of HIV-1 and VSVDG-CC4 Infection in Jurkat
Cells
Duplicate cultures of Jurkat cells were infected with HIV-1 IIIB at
day 0 and either superinfected with VSVDG-CC4 5 days later (closed
squares) or propagated without superinfection (open squares). The
percentage of HIV1 cells was determined by immunofluorescence
microscopy on the days indicated (A). The percentage of HIV1 cells
that were also infected with VSVDG-CC4 was determined by immu- Figure 7. Effect of VSVDG-CC4 Infection onProduction of Infectious
nofluorescence microscopy to detect VSV N protein (B). One hun- HIV-1 and on Release of RT
dred to two hundred cells were counted from multiple random fields
Media from Jurkat cell cultures was analyzed for infectious HIV titersto determine the percentages of cells staining positive for HIV or
and for RT activity as described in Experimental Procedures. TitersVSV antigens.
(A) were performed in triplicate and are reported as TCID50/ml (open
squares, HIV-infected only; closed squares, HIV plus VSVDG-CC4).
Titers determined by this assay were consistent with titers deter-
mined by an indirect immunofluorescence assay detecting HIV anti-
gens. RT activity (B) is reported in total counts per minute (cpm)addition toJurkat cells that had been infected with HIV-1
bound to the DEAE paper after subtraction of a backgrounds offor 5 days as in Figure 6. Table 1 shows that anti-CD4
less than 50 cpm (open squares, HIV-infected only; closed squares,completely eliminated the VSVDG-CC4 infection while
HIV plus VSVDG-CC4; open triangles, VSVDG-CC4-infected only).
antibody to G did not. Similarly, preincubation of the The numbers plotted are the average of duplicates that agreed
HIV-infected cells with a polyclonal anti-gp120 antibody within 5%. Samples were collected from Jurkat cultures on the
completely prevented infection by VSVDG-CC4. indicated days.
Because CD4 can bind MHC class II on cell surfaces
(Doyle and Strominger, 1987), it was conceivable that
some low level of infection could occur after binding of
express HIV-1 envelope protein. Infection of these cellsVSVDG-CC4 to MHC class II on cells, although this
by VSVDG-CC4 is neutralized by antibody to CD4 addedwould not be expected without a membrane fusion pro-
to the virus or by antibody to HIV gp120 added to thetein. To test this possibility, we used Daudi cells, a lym-
cells.phocyte cell line known to express abundant quantities
Our results showed that in a mixed population of cells,of MHC class II protein (Till et al., 1988). These cells
were readily infected by wild-type VSV, but we did not
observe any infection by VSVDG-CC4. Table 1. Neutralization of VSVDG-CC4 Infectivity
Percent Percent
Antibodya HIV1 Cellsb VSV N1 Cellsb
Discussion
None 60 39
anti-VSV G 59 37
We have derived a novel virus, VSVDG-CC4, that lacks anti-CD4 74 0
the VSV G protein gene and expresses instead the HIV-1 anti-HIV gp120 71 0
receptor and coreceptor molecules CD4 and CXCR4.
a Viruses grown on BHK cells not expressing VSV G were incubated
This novel virus is defective for entry into normal cells with anti-VSV G or anti-CD4, or cells were incubated with anti-HIV
but can be propagated on cells expressing a comple- gp120 prior to mixing of virus and cells.
menting VSV G protein. The complemented virus can b HIV1 and VSV N1 cells were identified by indirect immunofluores-
cence microscopy as in Figures 5 and 6. Approximately 100 cellsthen be grown on cells not expressing G protein, where
from random fields were counted for each determination. The per-it buds particles containing CD4 and CXCR4 in the viral
centage of cells positive for HIV antigens or VSV N protein is indi-membrane. This VSVDG-CC4 virus can enter and propa-
cated.
gate only in cells that are first infected with HIV-1 and
Cell
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about half of which were HIV-1-infected and half were that are worth noting. First, because VSVDG-CC4 is spe-
cifically targeted to cells already infected with HIV-1,uninfected, superinfection with VSVDG-CC4 ultimately
limited production of infectious HIV-1 to levels that were the VSVDG-CC4 infection level would be expected to
parallel HIV infection and thus decline with HIV clear-barely detectable or undetectable, at least 300-fold to
104-fold lower than HIV titers produced by control cells ance. Second, VSVDG-CC4 encodes only human pro-
teins as its envelope proteins and thus would not inducethat were not superinfected with VSVDG-CC4. This re-
duction presumably is the result of killing of the HIV-1- production of neutralizing antibodies. The internal VSV
proteins would be expected to induce cytotoxic T cellinfected cells by the VSVDG-CC4 virus. The reduction in
HIV-1 titers was greater than would have been predicted responses, but such responses might help in clearing
HIV infection by rapidly killing cells infected with HIV-1from analysis of the number of HIV-1-infected cells or
from RT assays. The number of HIV1 cells was reduced and VSVDG-CC4. Third, mutations to drug resistance
are rapidly selected in HIV-1, but resistance to infectionabout 10-fold by the VSVDG-CC4 infection, and the re-
lease of RT was reduced to a similar extent. In consider- by VSVDG-CC4 would require loss of HIV's ability to
bind CD4 or coreceptor and would therefore not being the mechanism of VSVDG-CC4 action, this discrep-
ancy is reasonable since VSVDG-CC4 will target and kill selected.
Given the complexity of HIV-1 infection in humans,those cells expressing HIV envelope protein and thus
select for cells that produce little or no HIV envelope. clinical trials will be required to determine the value of
our approach. The CXCR4 coreceptor (Feng et al., 1996)Such cells would still score positive for HIV-1 antigen
production and would produce normal levels of HIV- is used by the T cell±tropic syncytium-inducing HIV-1
strains that typically predominate in late stage HIV dis-like particles containing RT, but the majority of these
particles would be noninfectious. ease (see Moore, 1997, for review). The VSVDG-CC4
virus might therefore be directly applicable in limitingThe persistence of a low level of both HIV-1 and
VSVDG-CC4 coinfection for over 1 month in culture indi- HIV-1 production in late stage patients. Clinical stage
is strongly associated with all measures of virus loadcates that both viruses are continuing to replicate and
that they have reached a balance. Based on our analysis (reviewed by Weiss, 1993), and HIV virus load might
be significantly reduced by VSVDG-CC4. Because theso far, it seems unlikely that VSVDG-CC4 will ever com-
pletely eliminate the HIV-1 infection in the culture. This VSVDG-CC4 virus can replicate continuously in HIV-
infected cells, multiple treatments might not be required.low level persistence may occur because VSVDG-CC4
can only infect HIV-1-infected cells after gp120/41 is We are also introducing genes for other coreceptors
such as CCR5 or CCR3 into the VSVDG-CD4 virus in anexpressed on the cell surface and such cells likely re-
lease some HIV-1 before they are killed. attempt to target macrophage-tropic HIV-1 strains that
typically predominate early in HIV infection (Choe et al.,The VSVDG-CC4 virus infects cells that have already
been infected with HIV-1, but it may also be fusing di- 1996; Doranz et al., 1996; Schuitemaker and Miedema,
1996; Moore, 1997).rectly with HIV-1 virions. Such fused viruses would con-
tain the nucleocapsids of HIV and VSV and might be Our results also illustrate an important aspect of VSV
budding and assembly. Based on virus protein yieldsable to initiate infection if sufficient gp120/41 were still
present on the membrane. Such an infection would al- and titers, we estimate that each BHK cell infected with
wild-type VSV produces approximately 100,000 parti-most certainly favor replication of VSVDG-CC4, because
VSV would shut off cellular protein synthesis in 2 to cles, and up to 10% of these particles are infectious.
The deletion of the VSV G gene reduced particle yields3 hr, even before HIV had sufficient time for reverse
transcription and integration. Infection by these fused of VSVDG-CC4 or VSVDG-CD4 approximately 30- to 50-
fold, indicating a substantial role for G in promotingviruses could explain the presence of occasional cells
(Figure 5) that are makingVSV proteinsbut do not appear budding. However, despite this reduced budding, at
least 2,000 particles of VSVDG-CC4 or VSVDG-CD4 areto have synthesized HIV proteins. It is also possible that
VSV has inhibited HIV protein synthesis in these cells. produced from each BHK cell in the absence of G pro-
tein. The incorporation of CD4 and CXCR4 into theseInfection of uninfected cells by VSVDG-CC4 might also
occur if VSVDG-CC4 pseudotypes carrying HIV envelope particles is presumed to occur by a passive process of
protein trapping as virus buds from the cell surface,protein were generated in HIV-infected cells. Incorpora-
tion of the wild-type HIV envelope into VSV particles is because neither protein would be expected to contain
specific signals promoting incorporation. Because VSVextremely inefficient (Johnsonet al., 1997), and therefore
this latter mechanism would likely be rare. To test di- blocks host protein synthesis and expresses extremely
large amounts of its mRNA and proteins, CD4 andrectly for such pseudotypes, we carried out a short-
term infection of Jurkat cells with supernatants from CXCR4 are likely to be the major proteins present on
cell surface and therefore the major proteins in thecells coinfected with HIV-1 and VSVDG-CC4. VSV pro-
tein expression was not detected in these cells, while VSVDG-CC4 envelope.
Our results also suggest a general strategy of virusit was readily detected by using the same supernatant
to infect HIV-infected Jurkat cells. We conclude that the targeting to infected cells in cases where receptor(s)
recognized by viral envelope proteins are known andVSVDG-CC4(HIV) pseudotypes are extremely rare if they
exist at all. the viral envelope protein has membrane fusion activity.
Specific targeting of defective VSVs to kill other cellsAlthough our results indicate that the VSVDG-CC4
virus can control HIV infection in a T cell line, more work (e.g., cancer cells) might also be possible if genes for
specific antibodies and a membrane fusion protein wereis needed to determine if it will have therapeutic value.
There are however some positive aspects of this system incorporated into VSVs lacking the G gene.
Control of HIV-1 Infection by a Targeted Virus
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Experimental Procedures cell debris and nuclei were removed by centrifugation at 1,250 3 g
for 5 min, and virus was then purified twice by ultracentrifugation
at 120,000 3 g through a 20% sucrose solution containing 10 mMPlasmid Construction
Digestion with MluI and SphI was used to delete the entire VSV G Tris-HCl (pH 7.5) and 1 mM EDTA. Virus pellets were resuspended
and analyzed by SDS-PAGE (10% acrylamide). Gels were eithergene from pVSV-CD4 (Schnell et al., 1996b). The resulting plasmid
was designated pVSVDG-CD4. A plasmid encoding the CXCR4 pro- stained with Coomassie brilliant blue or transferred to nitrocellulose
membranes. Membranes were blocked with 5% low fat milk powdertein with an HA epitope tag was described previously (Berson et
al., 1996). CXCR4 was amplified by PCR from this plasmid with in TBST (10 mM Tris-HCl [pH 8.0], 150 mM NaCl, 0.05% Tween-20)
for 1 hr at room temperature and then incubated with an antibodyVENT polymerase (Stratagene) using primers 59-ACTGCCCGGGCT
CGAGGTTACCATGGAGGGGATCAG-39 and 59-AGCTGCGGCCGCT directed against CD4 (sheep a-CD4, AIDS Research Reference and
Reagent Program [ARRRP]) or an antibody 12CA5 (BoehringerAGCTTAGCTCCCGGGAAGAGATGCG-39. The first primer contains
an XhoI site and the second an NheI site (italic letters). The PCR Mannheim) directed against the HA epitope in CXCR4. Proteins were
visualized after incubation with horseradish peroxidase-conjugatedproduct was digested with XhoI and NheI and cloned into pVSV-XN1
(Schnell et al., 1996a) that was digested with XhoI and NheI. The donkey anti-sheep IgG or horseradish peroxidase-conjugated goat
anti-mouse IgG (Jackson Research) for 1 hr at room temperatureresulting plasmid was designated pVSV-CXCR4. The G gene was
deleted from pVSV-CXCR4 with XhoI and MluI. The coding sequence using enhanced chemiluminescence (ECL; Amersham) system.
for human CD4 was amplified from pCD4 (Shaw et al., 1989) by PCR
using primers 59-CCGGGTACCACGCGTACAATGAACCGGGGAGT Electron Microscopy and Labeling with
CCCTTTTAG-39 and 59-GGGCCCCTCGAGCGTGATATCTGTTAGTT Gold-Conjugated Antibodies
TTTTTCATACTC AAATGGGGCTACATGTCTTC-39. The first primer Virus particles from infection of approximately 107 cells on a 15 cm
contains an MluI site (italic letters); the second primer contains an dish were recovered from the culture medium by first pelleting cell
XhoI site (italic letters) and a VSV transcription stop±start signal debris at 1,500 3 g for 10 min. The virus was then concentrated
(underlined letters). The CD4 gene was inserted at the site of the G and purified by centrifugation as described above. Virus samples
deletion to generate a plasmid that was designated pVSVDG-CC4. were absorbed onto carbon-coated grids for 5 min and then blocked
with 1% BSA in PBS for 10 min at room temperature. The grids
were then placed on a 50 ml drop of anti-CD4 MAb OKT4 (ReinherzConstruction of a BHK Cell Line Expressing VSV G Protein
The tetracycline-regulated system employed was described pre- et al., 1979) diluted 1:50 in PBS containing 1% BSA. After 1 hr,
excess antibody was removed by placing grids sequentially ontoviously (Shockett et al., 1995). A VSV G gene was prepared from a
plasmid designated pBSG by digestion with XhoI. Extensions were five 50 ml drops of 1% BSA in PBS for 2 min each time. The grids
were then placed on a 50 ml drop of goat anti-mouse IgG (Fc) labeledfilled in with Klenow enzyme and the fragment ligated to pTet-Splice
(Life Technologies) that had been cleaved with EcoRV. The resulting with 15 nm gold particles (AuroProbe, Amersham). Unbound gold
conjugates were removed by five sequential 2 min washes with PBS.plasmid was called pTET-G. BHK cells on 10 cm plates (20% conflu-
ent) were transfected with 1 mg pTET-G and 10 mg pTet-TAk (Life The virus±immunogold complexes were then negative stained by
incubation of the grids for 4 min on 50 ml drops of 2% phosphotung-Technologies) using the CaPO4 method (mammalian transfection
kit; Stratagene). One day after transfection, 0.5 mg/ml tetracycline stic acid (pH 7.2). Excess stain was removed and the grids were air
dried. Images of viruses were obtained with a Zeiss EM910 electronwas added to suppress G protein expression, which is toxic to BHK
cells, and stable transfected cells were selected by adding 0.75 mg/ microscope.
ml geneticin (G418). Ten days after transfection, cell colonies were
isolated and, after induction by removal of tetracycline, they were Infection and Immunofluorescence Microscopy
screened for expression of VSV G protein by immunofluorescence of Infected Jurkat Cells
microscopy. Approximately 3 3 106 Jurkat cells (clone E6-1, ATTC #TIB-125)
were seeded in T-25 flasks and grown in RPMI medium supple-
mented with 10% FBS. Infection with HIV-1 strain IIIB was at anRecovery of VSV Recombinants
Baby hamster kidney cells (BHK-21, ATCC) were maintained in moi of approximately 0.01. At 5 days postinfection, cells were super-
infected with VSVDG-CC4 virus derived from 5 3 106 infected BHKDMEM (Dulbecco's modified Eagle's medium) supplemented with
5% fetal bovine serum (FBS). Cells on 10 cm dishes (z80% conflu- cells in 5 ml medium. As controls, one HIV-infected culture was not
superinfected, and a third culture was infected only with VSVDG-ent) were infected at an moi of 10 with vTF7-3 (Lawson et al., 1995).
After 1 hr, plasmids encoding the N, P, G, and L proteins and the CC4. Cells were collected for analysis at each time point as follows.
One half of the volume of the culture was collected, and an equalappropriate recombinant antigenome RNA were transfected into the
cells using a cationic liposome reagent containing dimethyldiocta- volume of RPMI supplemented with 10% FBS was added back to
the original cultures. Cells were pelleted at 1000 rpm for 5 min atdecyl ammonium bromide and phosphatidylethanolamine (Rose et
al., 1991; Lawson et al., 1995). Plasmid amounts were 10 mg of the 58C in an IEC Centra-7R refrigerated centrifuge (Fisher Scientific).
The media was discarded, cells were washed once in 5 ml PBS, andrespective full-length plasmid (VSVDG-CD4 or VSVDG-CC4), 3 mg
pBS-N, 5 mg pBS-P, 4 mg BS-G, and 1 mg pBS-L. Supernatants of pelleted again. The PBS was removed and cells wereresuspended in
100 ml PBS. The cells were then fixed in 1 ml of 3% paraformaldehyderecoveries were filtered through 0.22 mm filters, and 5 ml was used
to infect BHK-G cells on 10 cm plates that had been induced for for 1 hr at room temperature or overnight at 48C. After permeabiliza-
tion in 1% Triton X-100, cells were stained with a monoclonal anti-12 hr by removal of tetracycline. Supernatants of the first passage
were filtered twice through a syringe filter (0.1 mm pore size) to body to VSV N protein and with human polyclonal HIV immunoglobu-
lin (ARRRP), followed by rhodamine-conjugated anti-mouse andremove any vaccinia virus, and the viruses were then passaged on
4 3 106 BHK-G cells. Supernatants (10 ml) were titered on BHK-G FITC-conjugated anti-human antibodies (Jackson Research).
Cells were examined and photographed with 403 planapochro-cells and frozen at 2808C. For production of virus stocks, 2 3 106
BHK cells on 10 cm plates were infected for 2 hr with 10 ml superna- mat objective on a Nikon Microphot-FX microscope equipped for
epifluorescence.tants of VSVDG-CD4 or VSVDG-CC4 grown on BHK-G cells, washed
three times with phosphate-buffered saline (PBS), followed by addi- Infection of cells with HIV-1 or VSVDG-CC4 was monitored by
counting at least three random fields of cells that typically containedtion of 10 ml RPMI medium with 10% fetal bovine serum (FBS) or
10 ml DMEM with 5% FBS. At 16 hr after infection, supernatants 100 to 200 cells. Syncytia were counted as single cells.
were clarified by centrifugation and used for experiments or stored
at 2808C. Determination of HIV Titers
HIV titers were obtained using supernatants from infected cultures
and making serial 3-fold dilutions in 96-well plates. Ten thousandPreparation and Analysis of Viruses
For isolation of virions, a monolayer of BHK cells (z80% confluent) MT-2 cells (ARRRP) were added to each well, and the virus and
cells were mixed by pipeting. Plates were incubated at 378C for 3on a 10 cm dish was infected with VSVDG-CD4 or VSVDG-CC4
(moi 5 5), or VSV wild type (moi 5 0.01). At 16 hr after infection, to 5 days and scored for the presence of syncytia. Titers at each
Cell
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time point were performed in triplicate and two or more syncytia receptors CKR-5, CKR-3, and CKR-2b as fusion cofactors. Cell 85,
1149±1158.per well were counted as positive for HIV infection. Titers were
calculated as described previously (Reed and Muench, 1938) and Doyle, C., and Strominger, J.L. (1987). Interaction between CD4
are reported as 50% tissue culture infectious doses (TCID50) per ml. and class II MHC molecules mediates cell adhesion. Nature 330,
256±259.
Reverse Transcriptase Assays Dragic, T., Litwin, V., Allaway, G.P., Martin, S.R., Huang, Y., Naga-
Each assay was performed in 96-well plates in duplicate (Willey et shima, K.A., Cayanan, C., Maddon, P.J., Koup, R.A., Moore, J.P.,
al., 1988). Twenty-five microliters of reverse transcription reaction and Paxton, W.A. (1996). HIV-1 entry into CD41 cells is mediated
mix (0.05% NP-40, 50 mM Tris-HCl [pH 7.8], 75 mM KCl, 2 mM DTT, by the chemokine receptor CC-CKR-5. Nature 381, 667±673.
5 mM MgCl2, 5 units oligo(dT)12±18, 5 mg/ml poly(A)) was added Feng, Y., Broder, C.C., Kennedy, P.E., and Berger, E.A. (1996). HIV-1followed by addition of 10 ml of cell free culture supernatants. An
entry cofactor: functional cDNA cloning of a seven-transmembrane,additional 25 ml of reaction mix was added, containing 10 mCi/ml
G protein-coupled receptor. Science 272, 872±877.[a-32P]dTTP, and the reaction was placed at 378C for 90 min. Five
Florkiewicz,R.Z., and Rose, J.K. (1984). A cell line expressing vesicu-microliters of each sample was then spotted onto Whatman DE81
lar stomatitis virus glycoprotein fuses at low pH. Science 225,paper, which was allowed to air dry. The DE81 paper was then
721±723.washed in 23 SSC (0.3 M NaCl, 20 mM sodium citrate) buffer four
times, each time at room temperature for 5 min, followed by two 1 Fuerst, T.R., Niles, E.G., Studier, F.W., and Moss, B. (1986). Eukary-
min washes in 95% ethanol at room temperature. After air drying, otic transient-expression system based on recombinant vaccinia
the paper was exposed to a Molecular Dynamics PhosphorImager virus that synthesizes bacteriophage T7 RNA polymerase. Proc.
screen overnight. Samples were quantitated directly on the phos- Natl. Acad. Sci. USA 83, 8122±8126.
phorimager and by counting in a scintillation spectrometer after Johnson, J.E., Schnell, M.J., Buonocore, L., and Rose, J.K. (1997).
excision from the paper. Duplicates samples agreed within 5%. Specific targeting to CD41 cells of recombinant vesicular stomatitis
viruses encoding human immunodeficiency virus envelope proteins.
Neutralization of Infection by VSVDG-CC4 J. Virol. 71, 5060±5068.
Polyclonal sheep anti-CD4 serum and anti-gp120 serum (ARRRP) Knipe, D.M., Baltimore, D., and Lodish, H.F. (1977). Maturation of
were heat treated at 568C for 1 hr to inactivate complement. The viral proteins in cells infected with temperature-sensitive mutants
anti-VSV neutralizing monoclonal antibody (I1) was a mouse ascites of vesicular stomatitis virus. J. Virol. 21, 1149±1158.
fluid. Neutralizations were performed as follows. VSVDG-CC4 virus
Lapham, C.K., Ouyang, J., Chandrasekhar, B., Nguyen, N.Y., Dimi-(1 ml derived from z106 infected BHK cells) was mixed with 100 ml
trov, D.S., and Golding, H. (1996). Evidence for cell-surface associa-anti-CD4 or 100 ml anti-VSV for 1 hr at 378C, and then the mixture
tion between fusin and the CD4-gp120 complex in human cell lines.was added to z106 Jurkat cells that had been infected with an moi
Science 274, 602±605.of 0.01 HIV-1 IIIB 5 days previously. Alternatively, 100 ml anti-gp120
Lawson, N.D., Stillman, E.A., Whitt, M.A., and Rose, J.K. (1995).serum was added directly to 1 ml of HIV-infected Jurkat cells for 1
Recombinant vesicular stomatitis viruses from DNA. Proc. Natl.hr at 378C. Then 1 ml of VSVDG-CC4 was added to the cells. After
Acad. Sci. USA 92, 4477±4481.3 days, cells were pelleted at 1000 rpm in a clinical centrifuge for
5 min and washed once in PBS. Cells were fixed and stained to Maddon, P.J., Dalgleish, A.G., McDougal, J.S., Clapham, P.R.,
detect HIV and VSV N protein antigens. Weiss, R.A., and Axel, R. (1986). The T4 gene encodes the AIDS
virus receptor and is expressed in the immune system and the brain.
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